vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and HALOZYME THERAPEUTICS, INC. (HALO). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $451.8M, roughly 1.3× HALOZYME THERAPEUTICS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -31.3%, a 72.2% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $217.6M). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs 18.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
EXEL vs HALO — Head-to-Head
Income Statement — Q4 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $451.8M |
| Net Profit | $244.5M | $-141.6M |
| Gross Margin | 95.6% | 82.6% |
| Operating Margin | 39.3% | -20.6% |
| Net Margin | 40.8% | -31.3% |
| Revenue YoY | 5.6% | 51.6% |
| Net Profit YoY | 74.8% | -203.3% |
| EPS (diluted) | $0.89 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $451.8M | ||
| Q3 25 | $568.3M | $354.3M | ||
| Q2 25 | $555.4M | $325.7M | ||
| Q1 25 | $566.8M | $264.9M | ||
| Q4 24 | — | $298.0M | ||
| Q3 24 | $539.5M | $290.1M | ||
| Q2 24 | $637.2M | $231.4M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $-141.6M | ||
| Q3 25 | $184.8M | $175.2M | ||
| Q2 25 | $159.6M | $165.2M | ||
| Q1 25 | $139.9M | $118.1M | ||
| Q4 24 | — | $137.0M | ||
| Q3 24 | $118.0M | $137.0M | ||
| Q2 24 | $226.1M | $93.2M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 82.6% | ||
| Q3 25 | 96.6% | 84.4% | ||
| Q2 25 | 96.5% | 85.8% | ||
| Q1 25 | 96.5% | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | 96.8% | 83.0% | ||
| Q2 24 | 97.2% | 82.9% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | -20.6% | ||
| Q3 25 | 37.6% | 61.5% | ||
| Q2 25 | 33.6% | 62.2% | ||
| Q1 25 | 28.8% | 53.4% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | 25.2% | 56.3% | ||
| Q2 24 | 43.3% | 50.7% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | -31.3% | ||
| Q3 25 | 32.5% | 49.5% | ||
| Q2 25 | 28.7% | 50.7% | ||
| Q1 25 | 24.7% | 44.6% | ||
| Q4 24 | — | 46.0% | ||
| Q3 24 | 21.9% | 47.2% | ||
| Q2 24 | 35.5% | 40.3% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $-1.13 | ||
| Q3 25 | $0.65 | $1.43 | ||
| Q2 25 | $0.55 | $1.33 | ||
| Q1 25 | $0.47 | $0.93 | ||
| Q4 24 | — | $1.06 | ||
| Q3 24 | $0.40 | $1.05 | ||
| Q2 24 | $0.77 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $133.8M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $2.2B | $48.8M |
| Total Assets | $2.8B | $2.5B |
| Debt / EquityLower = less leverage | — | 43.89× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $133.8M | ||
| Q3 25 | $791.1M | $419.7M | ||
| Q2 25 | $1.0B | $61.9M | ||
| Q1 25 | $1.1B | $176.3M | ||
| Q4 24 | — | $115.8M | ||
| Q3 24 | $1.2B | $154.3M | ||
| Q2 24 | $1.0B | $187.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $48.8M | ||
| Q3 25 | $2.0B | $503.9M | ||
| Q2 25 | $2.1B | $332.7M | ||
| Q1 25 | $2.2B | $482.3M | ||
| Q4 24 | — | $363.8M | ||
| Q3 24 | $2.3B | $452.7M | ||
| Q2 24 | $2.1B | $289.4M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.5B | ||
| Q3 25 | $2.7B | $2.2B | ||
| Q2 25 | $2.8B | $2.1B | ||
| Q1 25 | $2.9B | $2.2B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $3.0B | $2.1B | ||
| Q2 24 | $2.8B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $219.0M |
| Free Cash FlowOCF − Capex | $332.4M | $217.6M |
| FCF MarginFCF / Revenue | 55.5% | 48.2% |
| Capex IntensityCapex / Revenue | 0.2% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $644.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $219.0M | ||
| Q3 25 | $49.0M | $178.6M | ||
| Q2 25 | $211.4M | $99.7M | ||
| Q1 25 | $240.3M | $154.2M | ||
| Q4 24 | — | $178.5M | ||
| Q3 24 | $271.3M | $115.4M | ||
| Q2 24 | $119.5M | $55.8M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $217.6M | ||
| Q3 25 | $46.2M | $175.6M | ||
| Q2 25 | $208.5M | $98.1M | ||
| Q1 25 | $236.3M | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | $263.1M | $113.9M | ||
| Q2 24 | $113.0M | $53.2M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 48.2% | ||
| Q3 25 | 8.1% | 49.6% | ||
| Q2 25 | 37.5% | 30.1% | ||
| Q1 25 | 41.7% | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | 48.8% | 39.3% | ||
| Q2 24 | 17.7% | 23.0% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.5% | 0.9% | ||
| Q2 25 | 0.5% | 0.5% | ||
| Q1 25 | 0.7% | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | 1.5% | 0.5% | ||
| Q2 24 | 1.0% | 1.1% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | 1.02× | ||
| Q2 25 | 1.32× | 0.60× | ||
| Q1 25 | 1.72× | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | 2.30× | 0.84× | ||
| Q2 24 | 0.53× | 0.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
Segment breakdown not available.
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
